Sale trumps Regeneron bid The sale to TTAM replaces a $256 million bid for 23andMe by drug maker Regeneron made in May. "We are pleased that the competitive bidding process has resulted in ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute, the ...

During the bankruptcy proceedings, New York-based Regeneron Pharmaceuticals won an auction to acquire the company for $256 million. Subsequently, a group of 27 states and the District of Columbia ...

Earlier, drug maker Regeneron Pharmaceuticals was set to buy 23andMe. Then a bankruptcy judge reopened the bidding process to allow for a bid from TTAM, which offered a higher price.

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth ...

Last month, 23andMe said that biotech firm Regeneron had won the bidding during a bankruptcy auction to buy the company for $256 million. The bidding reopened after TTAM made its unsolicited offer.

And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved.

Sale trumps Regeneron bid The sale to TTAM replaces a $256 million bid for 23andMe by drug maker Regeneron made in May. "We are pleased that the competitive bidding process has resulted in ...

23andMe also said that all customers would be emailed before the acquisition closes — with details on TTAM’s privacy commitments and instructions on how to delete data or opt out of research.